Mitigating Clinical Supply Chain Risk as the Pandemic Continues
This panel webinar discusses the importance of clinical supply agility and how to mitigate supply chain risk that comes along with clinical supply decisions.
Download NowWhen the COVID-19 pandemic began, questions arose on how to manage demand and forecasting in the midst of uncertainty. After the first wave, the industry took stock of lessons learned and began to apply those takeaways to mitigate risks moving forward. At the end of 2020, a new risk surfaced on how the sheer numbers of COVID-19 vaccines being manufactured and distributed may impact the clinical supply chain. Will this impact the clinical supply chain of other products, especially those that require cold chain? How should sponsors adjust forecasts to mitigate potential disruptions?
Strategy
Jan Pieter (JP) Kappelle is a Supply Chain Executive with 30 years of industry experience, of which 15 years were spent leading clinical trial supplies departments in global pharmaceutical and biotech companies. Trained as an Electronic and Quality Engineer, JP has a strong financial background and brings a methodical, analytical and process-oriented approach to his work. Coupled with his MBA and MSc in Supply Chain Management, JP has the unique ability to switch between strategic and operational discussions.
An energetic team player and trusted business partner, JP focuses on driving strategy and delivering results. JP also serves as the Global Clinical Supplies Group (GCSG) European Membership Officer and Master of Ceremony where he connects clinical supply professionals for the purposes of education, knowledge sharing and the development of industry best practices.